Antimicrobial Peptides against Multidrug-Resistant *Pseudomonas aeruginosa* Biofilm from Cystic Fibrosis Patients

Daniel Ben Hur, Gal Kapach, Naiem Ahmad Wani, Edo Kiper, Moshe Ashkenazi, Gill Smollan, Natan Keller, Ori Efrati, and Yechiel Shai

**ABSTRACT:** Lung infection is the leading cause of morbidity and mortality in cystic fibrosis (CF) patients and is mainly dominated by *Pseudomonas aeruginosa*. Treatment of CF-associated lung infections is problematic because the drugs are vulnerable to multidrug-resistant pathogens, many of which are major biofilm producers like *P. aeruginosa*. Antimicrobial peptides (AMPs) are essential components in all life forms and exhibit antimicrobial activity. Here we investigated a series of AMPs (D,L-K$_6$L$_9$), each composed of six lysines and nine leucines but differing in their sequence composed of L- and D-amino acids. The D,L-K$_6$L$_9$ peptides showed antimicrobial and antibiofilm activities against *P. aeruginosa* from CF patients. Furthermore, the data revealed that the D,L-K$_6$L$_9$ peptides are stable and resistant to degradation by CF sputum proteases and maintain their activity in a CF sputum environment. Additionally, the D,L-K$_6$L$_9$ peptides do not induce bacterial detachment cells, allowing biofilm formation against resistant bacterial biofilms.

**INTRODUCTION**

Cystic fibrosis (CF) is an inherited disease that affects the respiratory system. The disease is triggered by a mutation in a gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein, expressed primarily on epithelial cells. The CFTR regulates the transport of ions and the movement of water across the epithelial barrier. CFTR dysfunction causes a dehydrated thick mucus, promoting bacterial growth, leading to biofilm colonization, and affects components of innate immunity. The result is an exaggerated and ineffective airway inflammatory response, leading to airway tissue damage, eventually leading to respiratory failure. Chronic lung infections are the major cause of death among CF patients, and most of the infections involve colonization of the opportunistic multiresistant bacterium *Pseudomonas aeruginosa*. *P. aeruginosa* developed resistance mechanisms toward antibiotics by decreasing antibiotic uptake, modifying enzymes, and developing a high rate of mutation and behavioral changes, which give the bacteria tools to fight against antibiotics and immune system components. Altogether, these factors allow the pathogen to survive and persist for years despite antibiotic treatments.

*P. aeruginosa* specializes in forming sessile microcolonies that stick to a surface and each other, eventually forming a biofilm. These adherent cells are embedded within a self-produced matrix of extracellular polymeric substances (EPS), biofilm detachment cells, allowing biofilm formation on new surfaces. The EPS provide a barrier and protect the bacteria from harsh conditions such as host immune defense and antimicrobial agents.

AMPs are part of the innate immune system in all living forms and serve as the first line of defense against pathogens. In humans, AMPs are stored in phagocytes in large quantities that can be released when invading microorganisms are encountered to stop microbial proliferation. AMPs share biophysical characteristics as they are short and composed of positively charged amino acids and hydrophobic amino acids but are not conserved in their sequences. Generally, AMPs are unstructured, potentially forming amphipathic α-helical or β-sheet structures in the membrane. AMPs disrupt the bacterial membranes without a specific high-affinity target and are assumed not to evolve resistance in pathogens, although some do. AMPs bind to the bacterial cell wall by electrostatic interactions with the anionic components. The hydrophobic interactions between the AMP and the bacterial acyl chains allow cell wall permeation due to the amphipathic structure that enables non-receptor-mediated attraction. Several AMPs were found to be active against planktonic bacteria and biofilm, e.g., LL-37, histatin, and nisin.
However, these and many other AMPs were found to be toxic to eukaryotic cells at high concentrations; therefore, the discovery of new therapeutics is urgently needed.24–26 De novo-designed AMPs that have high potency against bacterial cells and are not toxic to eukaryotic cells are promising candidates.27–29

Recently, we have designed a de novo peptide family named D,L-K6L9.30 Several modifications were made on the secondary structure by a different arrangement of the amino acids in the sequence and/or a partial replacement of L-to-D amino acids in peptides.31–33 These modifications improved their antimicrobial activity and resistance to protease degradation and reduced the level of hemolysis.30,32,34 In addition, the mechanism of killing of these peptides via membrane perturbation relies upon the inner bacterial membrane diffusion ability.32 Our work strives to understand the properties of AMPs that are required for efficient activity against CF clinical P. aeruginosa isolates, which sheds light on the vital properties of a new treatment for bacterial biofilm. Herein, the D,L-K6L9 peptides are active against PAO1 and CF isolates of P. aeruginosa at a planktonic stage and can inhibit and degrade biofilm in clinical and artificial CF sputum surroundings.

### RESULTS

#### Properties of the Antimicrobial and Antibiofilm Activities of AMPs

We investigated the antibiofilm and antimicrobial activities of a series of peptides containing nine leucines and six lysines each, with a net charge of +7 (Table 1). The parental peptide (Amp1L) has an α-helical structure and is toxic to mammalian cells.32 In contrast, Amp1D, Seg5D, and Seg6D, in which L-amino acids have been replaced with their D-enantiomers at positions 3, 6, 8, 9, and 13, resulted disruption in the secondary structure and hydrophobicity of the peptides (Table 1 and Figure S1).30 Similarly, the hydrophobic moment varies, which predicts an increase in the permeability of the AMP to the membrane35 (Table 1). Furthermore, in PE/PG phospholipid membranes and upon LPS interaction, it has been reported that these peptides have mixed α-helical, β-sheet, and random coil structures.30,32 Hydrophobic interactions stabilize the formation of a higher level of α-helix in Amp1D compared with those of the others.30,32 The biofilm inhibition and degradation mechanisms of the D,L-K6L9 peptides are surface adhesion, bacterial binding, and direct killing.30 Together with the D,L-K6L9 peptides, a well-known antimicrobial and antibiofilm peptide, human cathelicidin LL-37, was tested as a positive control (Table 1 and Figures S1 and S2). Amp1L, which consists of all of the L-amino acids of Amp1D, was used as a control for the protease stability of the D,L-K6L9 peptides in CF sputum (Table 1 and Figures S1 and S2).

#### Selection of Clinically Isolated CF Patient P. aeruginosa

Thirty-one clinical P. aeruginosa multidrug-resistant (MDR) isolates from CF patients were collected by Tel-Ha’Shomer hospital and verified as P. aeruginosa by MALDI-TOF mass spectrometry (Table S1). The isolates were tested for their sensitivity to different commercial antibiotics by BD-Phoenix identification panels (Tables S1 and S2). The data included the sensitivity of each isolate to clinically used antibiotics and revealed the difference between the isolates in their sensitivity to the same antibiotic (Tables S1 and S2). We determined the antimicrobial activity of the AMPs only on CF P. aeruginosa clinical isolates that could grow under laboratory conditions. The isolates were taken to investigate the activity of the D,L-K6L9 peptides by a minimal inhibitory concentration (MIC) assay (Table S1).

#### Activity of the AMPs against Clinical Isolates of P. aeruginosa from CF Patients

The AMPs listed in Table 1 were evaluated for their antimicrobial activity against planktonic bacteria using the MIC assay in a standard broth microdilution method. Human cathelicidin LL-37 and colistin were used as a positive control.22 The data revealed different MIC values for the different peptides (Table 2). LL-37 and Seg5D showed the highest diversity in their MICs among the tested isolates (Table 2). Although some isolates did not show a robust response (MIC > 25 μM), it is still considered a potent concentration. Seg6D showed antimicrobial activity (MIC ≤ 12.5 μM), and Amp1D was the most potent peptide against all of the tested isolates (MIC ≤ 3.12 μM) (Table 2).

#### Inhibition of CF Biofilm Formation at Sub-inhibitory Peptide Concentrations

Inhibition of biofilm formation was tested in a U-bottom microtitre 96-well plate without agitation to allow the bacteria to attach to the dish. Bacteria were allowed to form biofilm in the presence of the AMPs, and the biofilm biomass was measured using the crystal violet (CV) staining method. The antibiofilm activity was tested at MIC and sub-MIC concentrations for 19 isolates (Figure 1 and Figure S3). Two isolates, 94 and 95, did not successfully form biofilm and therefore are not presented. The peptides at the MIC concentration inhibited the formation of all of the biofilms of the clinical isolates except for clinical isolate 59 (Figure S3). Our data revealed a high degree of diversity in antibiofilm activity against the various isolates. LL-37 and Amp1D inhibited biofilm formation of clinical isolate 59 by ~30% and ~50%, respectively, in terms of MIC concentration (Figure S3), while Seg5D and Seg6D lost their activity (Figure 1A–D). Amp1D reduced at least 40% of the biofilm biomass compared to that of the untreated form (Figure 1D).
Table 2. MIC<sub>50</sub> Values (micromolar) of CF Patient Isolates of P. aeruginosa<sup>a</sup>

| isolate no. | LL-37 | Seg5D | Seg6D | Amp1D |
|------------|-------|-------|-------|-------|
| 24         | 12.5  | 25    | 12.5  | 3.12  |
| 25         | 3.12  | 6.25  | 6.25  | 1.56  |
| 29         | 1.56  | 6.25  | 1.56  | 1.56  |
| 40         | 12.5  | 25    | 12.5  | 1.56  |
| 46         | 1.56  | 3.12  | 1.56  | 0.78  |
| 52         | 1.56  | 12.5  | 6.25  | 1.56  |
| 53         | 6.25  | 6.25  | 6.25  | 1.56  |
| 59         | 6.25  | 25    | 6.25  | 1.56  |
| 71         | 12.5  | 25    | 12.5  | 3.12  |
| 72         | 6.25  | 25    | 12.5  | 3.12  |
| 82         | 1.56  | 3.12  | 1.56  | 1.56  |
| 94         | 6.25  | 25    | 12.5  | 3.12  |
| 95         | 1.56  | 3.12  | 1.56  | 0.78  |
| 99         | 3.12  | 25    | 12.5  | 1.56  |
| 172        | 1.56  | 25    | 6.25  | 1.56  |
| 238        | 25    | 25    | 6.25  | 3.12  |
| 251        | 1.56  | 6.25  | 3.12  | 1.56  |
| 629        | 12.5  | 25    | 12.5  | 3.12  |
| 995        | 12.5  | 6.25  | 6.25  | 3.12  |
| PAO1       | 3.12  | 12.5  | 6.25  | 1.56  |

<sup>a</sup>The MIC (micromolar) was measured by a serial dilution method performed in a 96-well polystyrene plate. Plates were incubated for 24 h at 37 °C followed by absorbance (600 nm) measurements for bacterial growth.

Moreover, Amp1D was found to inhibit biofilm in clinical isolates 24, 52, 53, and 71 and more at sub-inhibitory concentrations (Figure S3). For isolates 24, 25, 46, 53, 71, 72, 99, and 629, antibiofilm activity was observed at sub-inhibitory concentrations on all of the tested peptides (Figure S3). Interestingly, in isolates 24, 25, 46, 99, and 995, the inhibition of biofilm formation in all of the tested concentrations was maintained solely by Seg6D and Seg5D (Figure S3). From a micromolar concentration point of view, Amp1D was the most active AMP against most samples and was potent against all isolates at 1.56 μM (Figure 1A–D). A comparison of the inhibitory activity between the tested AMPs was made to analyze the most CF P. aeruginosa biofilm inhibitor AMP. Amp1D was found to be the most inhibitory AMP at 1.56 μM and maintained its activity in moderate mode once the concentration was reduced by half (Figure 1E). Moreover, AMPs were evaluated in a dose-dependent manner, revealing that Amp1D has the highest correlation (r = 0.718) between MIC dilution and biofilm inhibition (Figure 1F). However, LL-37 and Seg5D displayed similar correlations (r = 0.58 and r = 0.59, respectively), and Seg6D showed an r of 0.623 and validated that Seg5D and Seg6D preserve their activity at low concentrations (Figure 1F).

**D<sub>L</sub>-K<sub>L</sub>L<sub>9</sub> Peptides and LL-37 Degradation Biofilms of the Clinical Isolates.** We further investigated the activity of the AMPs to degrade established biofilms from CF P. aeruginosa clinical isolates. The biofilm was allowed to grow prior to the addition of peptides in serial dilutions. The biofilm biomass was evaluated using CV staining. The percentage of the biofilm biomass was different between isolates and peptides. Except for clinical isolate 59, all of the D<sub>L</sub>-K<sub>L</sub>L<sub>9</sub> peptides at 50 μM degrade the biofilm biomass by at least 60% (Figure S4). Seg5D, Seg6D, and LL-37 exhibited a lower biofilm degradation activity in isolate 59 of ∼40% (Figure S4).

In contrast, Amp1D maintained its degradation activity at lower concentrations in isolate 59 (Figure S4). For clinical isolates 24, 40, 53, and others, degradation occurred at sub-MIC concentrations on all of the peptides (Figure S4 and Table 2). Seg5D showed the most efficient biofilm degradation activity at sub-MIC concentrations against all of the isolate biofilms except biofilm isolate 82 (Figure S4). Generally, all of the clinical isolate biofilms were degraded by at least two of three D<sub>L</sub>-K<sub>L</sub>L<sub>9</sub> peptides at their MIC values by 30% (apart from isolate 82). LL-37, Seg5D, and Seg6D degraded ∼50% of most established biofilm at 12.5 μM (Figure 2A–C). Amp1D degraded ∼75% of the established biofilm of most of the isolates at 12.5 μM (Figure 2D). In contrast to the inhibition results, LL-37 did not show an advantage in its degradation activity on isolated sample 59 compared to the other AMPs (Figure 2A). Amp1D was found to have the most potent and broad-spectrum biofilm degradation activity compared to those of other AMPs at high concentrations of 12.5–50–12 μM (Figure 2E). At concentrations of <12.5 μM, all AMPs demonstrated the same degradation level (Figure 2E).

Furthermore, Amp biofilm degradation was evaluated in a dose-dependent manner. We found that Amp1D has the highest correlation (r = 0.743) between the concentration and the biofilm degradation rate (Figure 2F). Seg6D displayed a correlation (r = 0.709) that was the same as that of LL-37 (r = 0.694), which are less dose-dependent on biofilm degradation. However, Seg5D was found to have the lowest dose-dependent manner among all des with an r = 0.662 correlation (Figure 2F). Overall, our findings suggested that D<sub>L</sub>-K<sub>L</sub>L<sub>9</sub> peptides possess biofilm inhibition and biofilm degradation activity against most of the clinical MDR isolates.

**Antibiofilm Activity of Amp1D against P. aeruginosa CF Isolate and PAO1 Biofilm in Artificial Sputum Media (ASM).** Artificial sputum medium (ASM) is a homogeneous and nonviscous culture medium containing the components of CF patient sputum composed of amino acids, mucin, free DNA, etc. 36–59 ASM mimics the CF airway during P. aeruginosa infection, thus allowing the formation of self-aggregating biofilm structures and population variance. The ASM assay was tested against three CF clinical P. aeruginosa isolates and PAO1 (Figure 3). The three CF clinical P. aeruginosa isolates and PAO1 were allowed to grow for 72 h, and then the bacteria were treated with LL-37, Seg5D, and Seg6D for 24 h. After the treatment, we evaluated the biofilm viability using resazurin. Peptides LL-37, Seg5D, and Seg6D were less active in BM2 surroundings than in ASM surrounding at 12.5–100 μM (Figure 3A–D). Amp1D was found to be active against all CF isolates and PAO1 at 100 and 50 μM (Figure 3A–D). Isolates 24 and 82 and PAO1 were sensitive to Amp1D at 25 μM with 41.24%, 57.94%, and 66.7% biofilm viability, respectively (Figure 3A,C,D).

**Stability of the AMPs against Proteolysis in CF Sputum.** CF sputum in patients contains proteases, mucin, DNA, and ions. In addition, neutrophil elastase was found to be present at high concentrations and could degrade and deactivate antimicrobial peptides. 30 We tested whether the D<sub>L</sub>-peptides (Seg5D, Seg6D, and Amp1D) would demonstrate resistance to proteolytic degradation in CF sputum. The all-L-peptide (Amp1L) was used as a control as it shares the same amino acid composition as Amp1D but does not contain any D-amino acids (Table 1). The peptides were added to the diluted sputum to a final concentration of 100 μM, and the mixture was incubated at 37 °C for various time intervals.
Using RP-HPLC, residual peptide concentrations were determined. First, we conducted the experiments for all of the peptides for 6 h. LL-37 was fully degraded after 30 min, and Amp1L was degraded by ∼70% after 3 h and eventually degraded by ∼80% after 6 h. In contrast, Amp1D, Seg5D, and Seg6D were protected entirely from degradation after 6 h (Figure 4A). Therefore, we extended the incubation time for these AMPs to 48 h. Seg5D and Amp1D showed similar
Figure 2. Clinically isolated CF patient *P. aeruginosa* biofilm degradation in the presence of AMPs. *P. aeruginosa* bacteria were allowed to grow for 24 h and treated for 1 h with peptides. Surface-associated biofilm after treatment, examined using 0.1% CV staining followed by absorbance measurements at 590 nm. The results are reported relative to untreated biofilm. Background measurements with no added bacteria were performed as blanks. Data represent a 12.5 μM treatment by AMPs (A) LL-37, (B) Seg5D, (C) Seg6D, and (D) Amp1D. (E) Comparison of biofilm degradation for treatments with 1.56−50 μM AMP. (F) Median of the biofilm degradation within the AMP treatment. The data are presented as means ± standard errors. Statistical significance from untreated biofilm was determined by ANOVA. The significant difference in the biofilm degradation comparison between AMPs was determined by the Dunnettx method. (a) Significant difference between LL-37 and Amp1D (p ≤ 0.01) and between Amp1D and Seg5D and Seg6D (p ≤ 0.001). (b) Significant difference between Amp1D and LL-37 (p ≤ 0.05) and between Amp1D and Seg6D (p ≤ 0.01). (c) Significant difference between Amp1D and LL-37 (p ≤ 0.001), between Amp1D and Seg5D (p ≤ 0.01), and between Amp1D and Seg6D (p ≤ 0.05). Correlation was tested by Pearson’s R.
data are presented as means ± standard errors. The statistical significance from untreated biofilm was determined by ANOVA.

Bactericidal Activity of AMPs against *P. aeruginosa* CF Isolates and PAO1 in the Presence of CF Sputum. To test the activity of the peptides in an environment that mimics lungs of CF patients, sputum from CF patients was collected. *P. aeruginosa* CF isolates and PAO1 [each at 10⁶ colony-forming units (CFU)/mL] were added to diluted sputum together with 10 μM peptides. The mixture was then incubated at 37 °C for 1 h and plated on freshly made LB agar plates. The number of colonies was counted and compared to the untreated plates. Isolate 895 was inoculated to 10% CF diluted sputum to eliminate the possibility of a certain number in the untreated plates. Isolate 895 was inoculated to the CF sputum that gives a specific isolate an advantage. LL-37 lost its activity in the presence of CF sputum (Figure 5B). In summary, the D,L-K6L9 peptides are significantly stable to proteolytic degradation and remain stable in the CF sputum environment.

**Figure 3.** Effects of AMPs on *P. aeruginosa* CF isolate and PAO1 biofilm in ASM. *P. aeruginosa* CF isolates and PAO1 were grown in a 24-well plate with ASM for 3 days prior to exposure to different concentrations of AMPs for 24 h. Disruption of the biofilm was conducted by a 1 h incubation with cellulose. Viability was measured by a 2 h incubation with 0.02% resazurin. A plate reader with an excitation wavelength of 530 nm and an emission wavelength of 590 nm was used to measure fluorescence: (A) CF isolate 24, (B) CF isolate 46, (C) CF isolate 82, and (D) PAO1. The data are presented as means ± standard errors. The statistical significance from untreated biofilm was determined by ANOVA.

Visualizing *P. aeruginosa* PAO1 48 h Biofilm Distributed by Treatment with AMPs in the Presence of CF Sputum. CF sputum substances can neutralize AMPs, and the accumulation of the sputum supernatant may increase the viscosity of biofilms and enhance their resistance. To investigate the degradation activity of AMPs against biofilms grown in the presence of the sputum supernatant collected from CF patients, we incubated the biofilms for 48 h with 10% CF sputum and replaced the media after every 12 h. Following a 48 h incubation, 10 μM AMPs were added for 1 h, and the biofilms were stained with a live/dead cell kit for 1 h. Fluorescence microscopy images showed that the untreated biofilms contained a high proportion of live bacteria (Syto-9) compared with dead ones (propidium iodide) (Figure 5A). Next, the biofilms were subjected to a viability test using resazurin. Amp1D showed the highest level of biofilm degradation, followed by Seg6D and then Seg5D (Figure 5C–E). LL-37 showed the weakest biofilm degradation capability in the presence of CF sputum (Figure 5B). Overall, Seg6D and Amp1D were active when added to 10% CF sputum. LL-37 lost its potency in the presence of CF sputum (Figure 5F). The effect of Seg5D was moderate in CF sputum compared to the effects of Seg6D and Amp1D. However, the used concentration was 10 μM, which is a sub-MIC concentration.

D,L-K6L9 Peptides Inhibit and Degrade Established Biofilms of the Clinical Isolates in the Presence of CF Sputum. Inhibition and degradation of the formation of CF clinical *P. aeruginosa* isolate and PAO1 biofilms in the presence of CF sputum were tested in an ex vivo model. The peptide biofilm inhibitory activity was evaluated starting with the highest MIC concentrations. To imitate the CF lung environment, the mixed sputum from CF patients was diluted and inoculated with selected CF clinical *P. aeruginosa* isolates and PAO1. All of the D,L-K6L9 peptides significantly inhibit biofilm formation (Figure 6A). The synthetic AMPs preserved their inhibitory activity in CF sputum while LL-37 lost its activity as the concentration decreased (Figure 6A). Amp1D was the most potent peptide among all of the peptides tested. However, as the concentration decreased, it showed biofilm degradation kinetics and were degraded by only ~30% after 48 h (Figure 4B). Seg6D showed less moderate kinetics and was degraded by ~30% after 24 h, which was maintained for the next 24 h (Figure 4B). In summary, the D,L-K6L9 peptides are significantly stable to proteolytic degradation and remain stable in the CF sputum environment.
P. aeruginosa CF Isolates Do Not Evolve Constitutive Resistance to AMPs. Conventional antibiotic treatment frequently leads to the evolution of MDR bacteria. Resistance to AMPs is less common, but in some cases, it can be evolved by several mechanisms, including proteolytic degradation, surface modifications, and biofilm formation. We examined the ability of P. aeruginosa CF isolates to evolve resistance to D,L-K6L9 peptides and LL-37. The selected P. aeruginosa CF isolate and PAO1 bacteria from previous tests were exposed to four different AMPs (Table 1). Then, 4S parallel lineages with daily transfers were serially propagated in BM2 medium with increasing concentrations of the peptides. Cells that grew were transferred from the well into the fresh medium with increased concentrations of peptides (Figure 7A). The P. aeruginosa CF isolate resistance rate is represented by MIC folds, calculating the change in MIC. After prolonged exposure of 4S parallel lineages, the MIC values of most CF isolates and PAO1 increased but by <20-fold from the initial MIC except for isolate 46 to Seg5D and isolate 82 to Seg5D and Seg6D (Figure 7A). To determine if the resistance is constitutive, wells that reached the highest concentration were grown via three passages in fresh medium in the absence of peptides and were taken to assess their MICs (Figure 7B). All of the tested bacteria restored their initial MIC or close to it except isolate 24, with an MIC 12.02-fold that of Seg5D, and
isolate 82, with an MIC 6.87-fold that of Seg6D. PAO1 generates hyposensitivity toward Seg5D with a 3.34-fold MIC. In general, it was demonstrated that after prolonged exposure to AMPs, the CF isolates and PAO1 induce temporary and low resistance but did not develop constitutive resistance.

## DISCUSSION

To search for new potent CF sputum alternative antimicrobial agents, we investigated a family of D,L-K6L9 AMPs for their antimicrobial and antibiofilm activities against P. aeruginosa clinical isolates from CF patients. The CF P. aeruginosa isolates were found to be resistant to commercial antibiotics, which emphasizes the urgent need for new alternative drugs. All AMPs demonstrated antimicrobial activity against all CF isolates in the planktonic stage in BM2 surroundings. Although LL-37 is a promising candidate for dealing with bacterial biofilm infections in the clinic, it has low bioavailability and is toxic.44 We found that isolates highly resistant to commercial antibiotics were susceptible to the D,L-K6L9 peptides. For example, isolates 29 and 95, resistant to all antibiotics, are susceptible to our AMPs. Therefore, CF antibiotic-resistant isolates do not display cross-resistance to D,L-K6L9 peptides.
Figure 7. P. aeruginosa CF isolates and PA01 do not evolve constitutive resistance to AMPs. P. aeruginosa CF isolates and PA01 were serially propagated 45 times starting below the MICs of AMPs, which were increased. Growth was monitored by daily OD measurements. (A) MIC folds at the end of 45 parallel lineages. (B) MIC folds of constitutive resistance. The wells with the highest concentration were grown three times in fresh medium to determine their MIC after being washed with fresh medium. Statistical significance from DDW-treated P. aeruginosa determined by ANOVA.

and LL-37. These data indicated that the mode of action comprises pathways different from those of the conventional antibiotics. Moreover, the peptides displayed an antibiofilm activity against all clinical isolates except isolate 59. When biofilms form, while there is stress, the AMPs might be a stressor that allows isolate 59 to grow biofilm biomass better than the untreated bacteria. Moreover, isolate 59 was the most pigmented isolate, which was caused by the production of pyocyanin (blue) and pyoverdine (green) virulence. Pyocyanin increases solution viscosity, and pyoverdine can create a cationic barrier by rejecting other cationic molecules.

The antibacterial activity decreased in peptides Seg5D and Seg6D, which when tested at high concentrations may be due to the segregation of amino acids, which creates a charge cluster. In addition, the hydrophobic moment, which predicts an increase in the permeability of the AMPs to the membrane, increases in the following order: Seg5D < Seg6D < Amp1D. This explains the observed different activities (Table 1). However, the biofilm inhibition activity of Amp1D was found to fade at subinhibitory concentration, while Seg6D and Seg5D preserved their activity in the CF clinical P. aeruginosa isolates, indicating the importance of the ability of the AMPs to adhere to the bacteria to prevent biofilm formation at sub-inhibitory concentrations. When this is taken into consideration, the activities of these peptides are the same, once the peptides are penetrating the cell wall. These activity differences resulted from their diverse ability to diffuse through the bacterial cell wall. This phenomenon may occur in the biofilm, when the peptide concentration is low. Amp1D protrudes with its bactericidal activity and efficient biofilm inhibition and degradation. We assume that the biofilm degradation measurements were conducted following incubation with the AMPs for 1 h; considering the fact that the stability test showed that the peptides were stable for 48 h, it is possible that a longer incubation time would improve the effect of the D,L-K6L9 peptides. For further activity studies, we used ASM, which is a CF lung mimicking environment. In ASM, Amp1D degraded the biofilm while other AMPs lost their activity in the disruption of a 3 day biofilm. These findings highlight the importance of the positive charges spread along the AMPs to make the AMPs efficient in CF sputum. The lung environment of CF patients is rich in proteases that degrade native antimicrobial peptides. In contrast, the D,L-K6L9 peptides are stable in the sputum of CF patients. We found that the D,L-K6L9 AMPs are resistant to proteolytic degradation while all-L-amino acids peptides, Amp1L, and LL-37 are not. This partial replacement of L-to-D amino acids is sufficient to protect the peptide from degradation in the sputum. This property provides the peptides an advantage over L-peptides by extending their action time, which is reflected in better antibiofilm activity. We also observed that D,L-K6L9 peptides maintain their antibiofilm activity despite the presence of CF sputum, apart from Seg5D, whose MIC is higher than the used peptide concentration. In addition, we investigated the P. aeruginosa CF isolates to evolve resistance toward D,L-K6L9 peptides and LL-37. The data revealed that three selected clinical CF P. aeruginosa isolates and PA01 generated moderate inducible resistance but did not induce constitutive resistance toward the AMPs. Isolate 82 induced hyposensitivity to Seg5D and Seg6D, which are the change cluster peptides, indicating the importance of the charge distribution in AMPs. It might be the key property to prevent the development of AMP resistance. D,L-K6L9 peptides maintain their antibiofilm activity in the presence of CF sputum due to their low level of proteolytic degradation toward proteases and low salt sensitivity. On the contrary, natural AMPs, such as LL-37, are unstable, sensitive to salt, and toxic. Because exogenic LL-37 loses its activity in CF sputum, treatment of patients with it may be detrimental, which can be reflected in other endogenous AMPs in natural surroundings. Combining all of the properties, our study suggests that synthetic peptides may be useful for treating CF-associated lung infections in contrast to LL-37. In summary, D,L-K6L9 peptides exhibited efficient antimicrobial activity against all CF isolates. Importantly, D,L-K6L9 peptides are more resistant to sputum proteases than L-peptides and do not induce constitutive AMP resistance. The possibility of inducing constitutive resistance was lower. Altogether, Amp1D as the most powerful AMP has antimicrobial and antibiofilm activity in CF sputum, is resistant to proteolytic degradation, and is quite unlikely to induce bacterial resistance. In addition to more than one AMP treatment, rotational medication/synergism in AMPs might be useful in preventing resistance and/or a combination therapy with antibiotics to enhance their therapeutic potential.

CONCLUSIONS

We investigated a series of AMPs composed of six lysines and nine leucines with both L- and D-amino acids that differ in sequence. All of the peptides were tested against P. aeruginosa planktonic bacteria and biofilms isolated from CF patients. In addition of having strong antimicrobial and antibiofilm activity in the CF sputum environment, D,L-K6L9 peptides are stable in sputum and resistant to degradation by CF sputum proteases. Moreover, this peptide family is quite unlikely to induce resistance. The D,L-K6L9 peptides are short peptides that are easy to produce with a high yield of product, highlighting them as promising candidates for CF treatment.

EXPERIMENTAL SECTION

Chemicals and Materials. All of the reagents for the synthesis of the peptides were obtained from commercial sources and used without further purification. Fmoc amino acid coupling reagents [N,N′-diisopropylcarbodiimide (DIC) and ethyl cyano hydroxymoacetate (oxyma)] were purchased from Calbiochem/Novabiochem AG (Lauffelinger, Switzerland). Trifluoroacetic acid (TFA), piper-
idine, and trisopropylsilane (TIS) were purchased from Sigma-Aldrich. Solvents for peptide synthesis, purification, and analysis, including N,N-dimethylformamide (DMF), dichloromethane (DCM), diethyl ether, and acetonitrile (ACN), were obtained from Bio-Lab Ltd. The rim amide resin (0.57 mmol/g) was purchased from Iris Biotech Gmbh, and the manufacturer’s reported loading was used to calculate the yields of the final product. Colistin and CV (C3886) were purchased from Sigma-Aldrich (Rehovot, Israel). Sterile 96-well U-bottom (BN36010096D) and flat bottom (BND903C5L) polystyrene plates were purchased from Bar- Naor (Ramat Gan, Israel). Basal Medium 2 (BM2) and Luria-Bertani (LB) medium were provided by the Weizmann Bacteriology Unit. Experiments were performed in at least three biological repeats with technical repeats.

**Peptide Synthesis and Cleavage.** Peptides were synthesized by an automated peptide solid-phase synthesizer (CEM Liberty Blue peptide synthesizer) on resin amide 0.57 mmol/mg MBHA resin, using the Fmoc solid-phase strategy. To synthesize the peptides, Fmoc-Lys(Boc)-OH and Fmoc-Leu(Boc)-OH were used. The D-enantiomers of Fmoc-Lys(Boc)-OH and Fmoc-Leu(Boc)-OH in D- L-K,L peptides are involved at positions 3, 6, 8, 9, and 13. The resin-bound peptide was washed thoroughly with DMF and then DCM, dried, and cleaved. Cleavage was performed using 95% TFA, 2.5% water, and 2.5% TIS for 120 min at room temperature. The crude peptides were washed from the resin using TFA, precipitated using cold diethyl ether, and dried in air.

**Peptide Purification.** The purification of the peptides was performed by reverse-phase high-performance liquid chromatography (RP-HPLC) on an Agilent Technologies 1200 Series instrument with a reversed-phase Vydac C18 column (Thermo Fisher Scientific, 250 mm × 4.6 mm, 5 μm particle size, 250 μm × 10 mm) at a flow rate of 1.8 mL/min and monitored with an ultraviolet (UV) detector at 215 nm. Linear gradients of 20% to 90% acetonitrile in water containing 0.1% TFA were used for peptide purification for 40 min. Final products were obtained by freeze-drying the collected pure fractions.

**HPLC Analysis.** The purity of the peptides was determined using RP-HPLC on an Agilent Technologies 1260 Infinity II spectrometer with a C18 reversed-phase column (Thermo Fisher Scientific, 250 mm × 4.6 mm, 5 μm particle size) at a flow rate of 0.6 mL/min using a gradient of 10% to 90% ACN in water containing 0.1% TFA for 40 min with UV detection at 215 nm. The molecular masses of all of the peptides were determined by TOF-MS. The purity of all peptides examined for biological activity was >95%.

**Collection of Sputum from CF Patients and Isolation of P. aeruginosa.** Sputum samples from 31 CF patients were collected and transferred to the bacteriology laboratory at Sheba hospitals center, Tel-Hashomer. All 31 samples were subcultured on blood agar plates (BAP) and transferred to LB plates. The suspensions were stored at −80 °C in LB medium containing 17% glycerol. The samples were verified as *P. aeruginosa* by MALDI-TOF mass spectrometry using the Bruker Microflex LT, also called the MALDI Biotyper (MBT). The MALDI Biotyper (MBT) is an automatic device that uses the linear MALDI-TOF/MS technology to rapidly identify organisms on the basis of the mass of their proteins (mass spectrometry). Biomass from a colony is sampled and applied to 96 wells on a stainless steel target plate. A matrix of α-cyano 4-hydroxycinnamic acid (HCCA) dissolved in a solution containing a mixture of 2.5% trifluoroacetic acid, 50% acetonitrile, and 47.5% water was applied to the bacterial biomass on the target. A mixture of the matrix and sample co-crystallizes to form a solid deposit of the sample embedded in a matrix and loaded into the MALDI-TOF instrument. Additionally, this study used the *P. aeruginosa* PAO1 strain stored and grown under the same conditions as the clinical *P. aeruginosa* CF isolates.

**Identification of *P. aeruginosa* from CF Sputum.** *P. aeruginosa* was identified by the BD Phoenix Automated Microbiology System (Becton Dickinson). The system is intended for the rapid identification (ID) and antimicrobial susceptibility testing (AST) of clinically significant bacteria. Tests used in the Phoenix ID panels comprise a 45-well ID side that includes tests for fermentation, oxidation, degradation, and hydrolysis of various substances and an 85-well side containing dried antimicrobial agents in coordination with the hospital formulary as QC and growth wells. The technique involves exposing bacteria to decreasing concentrations of antimicrobial agents. The Phoenix panels were inoculated according to the manufacturer’s instructions as follows. A standardized inoculum of 0.5 McFarland was prepared in Phoenix ID Broth, gently vortexed, and measured using the BD PhoenixSpec nephelometer to ensure the correct inoculum; then, 25 μL of the inoculum was added to the Phoenix AST broth after the addition of one drop of the Phoenix AST indicator solution. Once inoculated with the solutions from both tubes, the panels were placed in the Phoenix instrument and continuously incubated at 35 °C. The instrument reads the panels every 20 min for ≤16 h. The final ID and AST results are transferred via the EpiCenter to the LIS.

**Antibacterial Activity.** The MIC of the peptides was tested as previously described with minor adjustments. Briefly, peptide activity was examined in sterile 96-well polystyrene plates (Bar- Naor BN36010096D). Overnight cultures of *P. aeruginosa* were washed and resuspended in a BM2 medium. Aliquots of 50 μL of suspended bacteria (1 × 10^8 CFU/mL) were added to 50 μL of BM2 medium containing peptides in serial 2-fold dilutions (final concentration between 0.78 and 50 μM). Plates were incubated for 24 h at 37 °C while being agitated. Inhibition of growth was assessed by absorbance measurements at OD_900 using a microplate auto reader. The MIC was defined as the concentration at which 90% inhibition of growth was observed after incubation for 24 h.

**Biofilm Inhibition.** The biofilm formation assay was performed as described for the MIC assay with some alterations and used either BM2 or CF patient sputum diluted 10-fold with BM2. Plates containing peptides at serial dilutions and bacteria were incubated for 24 h at 37 °C without agitation to allow biofilm formation. Unattached bacteria were then washed from plates, and the plates stained with 0.1% CV, followed by absorbance measurements at OD_900 using a microplate auto reader. Data are presented as a percentage of the biofilm biomass compared to biofilm formed by untreated bacteria ± standard error.

**Biofilm Degradation.** Degradation of biofilm was tested as described above for the MIC assay with some alterations. The medium was either BM2 medium or CF patient sputum diluted 10-fold with BM2. Plates containing peptides at serial dilutions and bacteria were incubated for 24 h at 37 °C without agitation to allow biofilm formation. Unattached bacteria were then washed from plates, and the plates stained with 0.1% CV, followed by absorbance measurements at OD_900 using a microplate auto reader. The results are presented as a percentage of the biofilm biomass compared to biofilm formed by untreated bacteria ± standard error.

**Artificial Sputum Media Assays (ASMs).** Assays were performed in a 24-well plate using three *P. aeruginosa* CF isolated strains and PAO1 used as a reference strain. ASM is CF patient sputum mimic medium. The assay was conducted as reported previously. Briefly, 4 g of salmon sperm DNA and 5 g of mucin from porcine stomach were slowly dissolved overnight in 250 mL of sterile water. Then, the solution was combined with 0.25 g of each essential and nonessential l-amino acid in 100 mL of sterile water (except l-cysteine, which was dissolved in 25 mL of 0.5 M potassium hydroxide, and l-tyrosine, which was dissolved in 25 mL of sterile water), 5.9 mg of diethylenetriaminepentaacetic acid (DTPA), 5 g of NaCl, 2.2 g of KCl dissolved in 100 mL of sterile water, and 5 mL of egg yolk emulsion. The pH was adjusted to 6.9 with 1 M Tris (pH 8.5). The volume was increased to 1 L with sterile water, and then the mixture filtered using a vacuum pump and Millipore Steritop filter units with a pore diameter of 0.22 μm. Overnight cultures of *P. aeruginosa* were washed and resuspended in BM2 to an OD of ~0.05 and then diluted 1:100 in fresh ASM. The total volume in each well was 1.8 mL. Plates were incubated for 3 days aerobically at 37 °C with agitation, allowing the *P. aeruginosa* biofilms to develop. After 3 days, 0.2 mL of AMPS was added at concentrations ranging from 12.5 to 100 μM and incubated for 24 h while being agitated. The biofilm was
disrupted by cellulase [100 μL of a 100 mg/mL solution (pH 4.6, diluted in 9.6 g/L citrate)] and then incubated for 1 h at 37 °C while being agitated. For each well, resazurin was added [100 μL of a 0.02% (v/v) solution] and incubated for 1–2 h at 37 °C. A TECAN Infinite200 PRO plate reader set at an excitation wavelength of 530 nm and an emission wavelength of 590 nm was used to measure fluorescence on black 96-well plates. The cell viability was calculated as (mean fluorescence of peptide-treated wells/mean fluorescence untreated control wells) × 100%.

Peptide Stability in CF Patient Sputum. The peptide stability in CF patient sputum was tested as previously described. Briefly, individual sputum samples from CF patients were pooled and diluted 10-fold with Dulbecco’s phosphate-buffered saline without calcium and magnesium. The suspensions were thoroughly mixed and then centrifuged at 1000 rpm for 10 min. nL-KLa peptides and LL-37 were added to the supernatant to a final concentration of 100 μM, and the mixture was incubated at 37 °C for several time intervals. The reaction was stopped by adding 10 μL of 10% hydrogen chloride (HCl) to the SS μL mixture. Residual peptide concentrations were determined via RP-HPLC on a Vydac C18 column (Grace Discovery Sciences, Deerfield, IL) using a linear gradient from 20% to 60% ACN in water (both containing 0.1% TFA) for 50 min. Data are presented as a percentage of peptide compared to the mixture without incubation ± standard errors.

Killing Assay in CF Sputum. Individual sputum samples from CF patients were pooled and diluted 10-fold with 10 mM phosphate buffer (pH 7.0). The suspensions were thoroughly mixed, centrifuged at 1000 rpm for 10 min, and filtered with a 0.2 μm filter. Supernatants were stored and used for killing assays and fluorescence microscopy, respectively. Then, 10^6 CFU/mL of P. aeruginosa was added to a 10% diluted sputum supernatant, followed by 10 μM peptides. The mixture was incubated at 37 °C for 1 h and then diluted and plated on freshly made LB agar plates.

Viability of 2 Day Biofilms in the Presence of CF Sputum Visualized by Confocal Microscopy. We visualized the P. aeruginosa biofilm using an Olympus FX1000 confocal microscope [60× objective lens (oil)]. A 200 μL volume of 10% diluted sputum supernatant was incubated with a P. aeruginosa inoculum (1× 10^9 CFU/mL) in eight-well chambered cover glass (Nunc, Thermo Scientific) for 48 h to allow biofilm formation. After treatment with peptides (10 μM) for 1 h, we evaluated the bacterial viability using a Filmtainer live/dead biofilm viability kit (Invitrogen, Life Technologies). Syto-9 (488 nm) marks live bacteria, and propidium iodide (559 nm) marks dead bacteria. For each well, resazurin was added [10 μL of a 0.02% (v/v) solution] and the mixture incubated for 2 h at 37 °C. A plate reader (TECAN Infinite200 PRO) set at an excitation wavelength of 530 nm and an emission wavelength of 590 nm was used to measure the fluorescence on a 96-well plate. The cell viability was calculated as (mean fluorescence of peptide-treated wells/mean fluorescence untreated control wells) × 100%.

Laboratory Evolution Experiment. The resistance evolution experiment was carried out in 96-well plates at a final volume of 100 μL as previously described[^15,25] with minor adjustments. All of the peptides were dissolved in DDW, and 5 μL of the peptide was added to 45 μL of BM2 in a 96-well plate. DDW was used as a negative control. Then, 1 × 10^6 CFU/mL of three P. aeruginosa CF isolates (24, 46, and 82) and PA01 were suspended in 50 μL aliquots of BM2 and inoculated into each well. The plate was incubated at 37 °C while being agitated for 24 h. Cell growth was monitored after each incubation period by measuring the OD at 600 nm, and 10 μL of the 100 μL culture was transferred to a new 96-well plate containing 90 μL of a fresh BM2 with increasing dosages of antimicrobial peptides. Only populations with the highest concentration were selected for further evolution. If no growth was seen, it was revived with the most recent passage with the appropriate concentration that showed growth. The peptide concentration was increased by 50% in successful growth and was continued for 45 serial transfers. At the end of the experiment, we removed 1.0 μL of bacteria from the well, which led to the highest concentration, that was spread on the LB plate and incubated overnight at 37 °C. Afterward, the MIC assay was performed on a population and a single colony. Next, a single colony was grown in BM2 for three passages without a peptide, and then MIC was determined. Cells during and after the evolution experiments were stored as glycerol stocks at ~80 °C.

Statistical Analysis. Statistical significance was determined using an ANOVA test (*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001) by Prism and R studio. The results are shown as means ± standard errors of the mean unless indicated otherwise. Experiments were repeated three times (biological repeats) in triplicate or duplicate unless indicated otherwise.

**ASSOCIATED CONTENT**

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00270.

Susceptibility test parameters of the Phoenix system, mass spectra of peptides, HPLC chromatograms of all peptides, inhibition of CF P. aeruginosa biofilm at sub-inhibitory concentrations of AMPs, and degradation of CF P. aeruginosa biofilms by AMPs (PDF)

**AUTHOR INFORMATION**

Corresponding Author

Yechiel Shai — Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel; orcid.org/0000-0003-4151-5513; Email: Yechiel.Shai@weizmann.ac.il

Authors

Daniel Ben Hur — Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
Gal Kapach — Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
Naeem Ahmad Wani — Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
Edo Kiper — Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
Moshe Ashkenazi — Pediatric Pulmonary Institute and National CF Center, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel
Gill Smollan — Microbiology Laboratories, Edmond and Lili Safra Children’s Hospital, Sheba Medical Center, Tel-Hashomer, Ariel University, Ramat Gan 52621, Israel
Natan Keller — The Department of Health Management, Ariel University, Ariel 40700, Israel; Microbiology Laboratories, Edmond and Lili Safra Children’s Hospital, Sheba Medical Center, Tel-Hashomer, Ariel University, Ramat Gan 52621, Israel
Ori Efrati — Pediatric Pulmonary Institute and National CF Center, Edmond and Lili Safra Children’s Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jmedchem.2c00270

**Notes**

The authors declare no competing financial interest.
We would like to thank Veikhman Lyudmila, Alla Falkovich and Guy Shmuel for mass spectrometry analysis, Vladimir Kiss and Melanie Bobstad Horev for technical assistance with the confocal imaging and Dr. Reinaat Nevo for help with image analysis. We also thank Dr. Yoel A. Klug, Dr. Etai Rotem, Batya Zarmi and Alon Nudelman for technical assistance and insightful discussions. I thank Shani Ben Hur for her support, attention, and long weekends we spent together in the lab while I continued working on the project. The Israeli Ministry of Science and Technology (Application 3-14316) and the Israel Science Foundation (Application 1944/20) supported this work.

ACKNOWLEDGMENTS

REFERENCES

ACN, acetonitrile; AMPs, antimicrobial peptides; ASM, artificial sputum medium; BM2, basal medium 2; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CFU, colony-forming units; CV, crystal violet; DCM, dichloromethane; DDW, doubly distilled water; DIC, N,N-dioisopropylcarbodiimide; DMF, N,N-dimethylformamide; EPS, extracellular polymeric substances; LB, Luria-Bertani; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; Oxyza, cyanohydroxymioacetate; PBS, phosphate-buffered saline; RP-HPLC, reverse-phase high-performance liquid chromatography; TFA, trifluoroacetic acid; TIS, trisopropylsilylane

ABBREVIATIONS

ACN, acetonitrile; AMPs, antimicrobial peptides; ASM, artificial sputum medium; BM2, basal medium 2; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CFU, colony-forming units; CV, crystal violet; DCM, dichloromethane; DDW, doubly distilled water; DIC, N,N-dioisopropylcarbodiimide; DMF, N,N-dimethylformamide; EPS, extracellular polymeric substances; LB, Luria-Bertani; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; Oxyza, cyanohydroxymioacetate; PBS, phosphate-buffered saline; RP-HPLC, reverse-phase high-performance liquid chromatography; TFA, trifluoroacetic acid; TIS, trisopropylsilylane

REFERENCES

(1) O’Sullivan, B. P.; Freedman, S. D. Cystic fibrosis. Lancet 2009, 373, 1891–1904.
(2) Saint-Criq, V.; Gray, M. A. Role of CFTR in epithelial physiology. Cell. Mol. Life Sci. 2017, 74, 93–115.
(3) Cohen, T. S.; Prince, A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 2012, 18, 509–519.
(4) Ciofu, O.; Tolkner-Nielsen, T. Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics. Front. Microbiol. 2019, 10, 913.
(5) Cystic fibrosis foundation patient registry annual data report 2015. Cystic Fibrosis Foundation, 2016.
(6) Costerton, J. W.; Stewart, P. S.; Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284, 1318–1322.
(7) Nuri, R.; Shprung, T.; Shai, Y. Defensive remodeling: How bacterial surface properties and biofilm formation promote resistance to antimicrobial peptides. Biochim. Biophys. Acta 2015, 1848, 3089–3100.
(8) Rončević, T.; Puzina, J.; Tossi, A. Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era? International Journal of Molecular Sciences 2019, 20, 5713.
(9) Fleming, H. C.; Wingender, J. The biofilm matrix. Nat. Rev. Microbiol 2010, 8, 623–633.
(10) Rossi, L. M.; Rangasamy, P.; Zhang, J.; Qiu, X. Q.; Wu, G. Y. Research advances in the development of peptide antibiotics. J. Pharm. Sci. 2008, 97, 1060–1070.
(11) Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389–395.
(12) Biswaro, L. S.; da Costa Sousa, M. G.; Rezende, T.; Dias, S. C.; Franco, O. L. Antimicrobial peptides and nanotechnology, recent advances and challenges. Front. Microbiol. 2018, 9, 855.
(13) Oren, Z.; Shai, Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 1998, 47, 451–463.
(14) Wani, N. A.; Ben Hur, D.; Kapach, G.; Stolovicki, E.; Rotem, E.; Shai, Y. Switching bond: generation of new antimicrobial peptides via the incorporation of an intramolecular isopeptide bond. ACS Infect Dis 2021, 7, 1702–1712.
(15) Shai, Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002, 66, 236–248.
(16) Sani, M.-A.; Separovic, F. How membrane-active peptides get into lipid membranes. Acc. Chem. Res. 2016, 49, 1130–1138.
(17) Kapach, G.; Nuri, R.; Schmidt, C.; Danin, A.; Ferrera, S.; Savidor, A.; Gerlach, R. G.; Shai, Y. Loss of the periplasmic chaperone skp and mutations in the efflux pump AcrAB-ToLC play a role in acquired resistance to antimicrobial peptides in Salmonella typhimurium. Front. Microbiol. 2020, 11, 189.
(18) Davies, E. V.; James, C. E.; Brockhurst, M. A.; Winstanley, C. Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model. BMC Microbiol. 2017, 17, 3.
(19) Spohn, R.; Daruka, L.; Lazar, V.; Martins, A.; Vidovic, F.; Grezal, G.; Mehi, O.; Kittsnes, B.; Szamel, M.; Jangir, P. K.; Csorgo, B.; Gyorkei, A.; Bodí, Z.; Farago, A.; Bodai, L.; Foldesi, I.; Kata, D.; Maroti, G.; Pap, B.; Wirth, R.; Papp, B.; Pal, C. Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance. Nat. Commun. 2019, 10, 4538.
(20) Yeaman, M. R.; Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55, 27–55.
(21) Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1999, 1462, 55–70.
(22) Overhage, J.; Campisano, A.; Bains, M.; Torfs, E. C.; Rehm, B. H.; Hancock, R. E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176–4182.
(23) Chennupati, S. K.; Chiu, A. G.; Tamashiro, E.; Banks, C. A.; Cohen, M. B.; Bleier, B. S.; Kofonow, J. M.; Tam, E.; Cohen, N. A. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am. J. Rhinol Allergy 2009, 23, 46–51.
(24) Di, Y. P.; Lin, Q.; Chen, C.; Montelaro, R. C.; Doi, Y.; Deslouches, B. Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Sci. Adv. 2020, 6, eaay6817.
(25) Marr, A. K.; Gooderham, W. J.; Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Current opinion in pharmacology 2006, 6, 468–472.
(26) Fukumoto, K.; Nagaoka, I.; Yamataka, A.; Kobyashi, H.; Yanai, T.; Kato, Y.; Miyan, T. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatric surgery international 2005, 21, 20–24.
(27) Cappiello, F.; Di Grazia, A.; Segev-Zarko, L.-a.; Scali, S.; Ferrera, L.; Galiotta, L.; Pini, A.; Shai, Y.; Di, Y. P.; Mangoni, M. L. Esculentin-1a-derived peptides promote clearance of Pseudomonas aeruginosa internalized in bronchial cells of cystic fibrosis patients and lung cell migration: biochemical properties and a plausible mode of action. Antimicrob. Agents Chemother. 2016, 60, 7252–7262.
(28) Degasperi, M.; Agostinis, C.; Mardrossian, M.; Maschio, M.; Taddio, A.; Bulla, R.; Scocchi, M. The anti-pseudomonal peptide BMAP18 is active in cystic fibrosis sputum and displays anti-inflammatory in vitro activity. Microorganisms 2020, 8, 1407.
(29) Luca, V.; Stringaro, A.; Colone, M.; Pini, A.; Mangoni, M. L. Esculentin(1–21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell. Mol. Life Sci. 2013, 70, 2773–2786.
(30) Segev-Zarko, L.; Saar-Dover, R.; Brumfeld, V.; Mangoni, M. L.; Shai, Y. Mechanisms of biofilm inhibition and degradation by antimicrobial peptides. Biochim. J. 2015, 468, 259–270.
(31) Domhan, C.; Uhl, P.; Kleist, C.; Zimmermann, S.; Umsatter, F.; Leotta, K.; Mier, W.; Wink, M. Replacement of l-Amino Acids by d-Amino Acids in the Antimicrobial Peptide Ranalexin and Its Consequences for Antimicrobial Activity and Biodistribution. Molecules 2019, 24, 2987.
Cystic fibrosis sputum. Activity against Pseudomonas aeruginosa in conditions mimicking combination with EDTA exerts strong antimicrobial and antibiofilm incorporation in the frog skin-derived peptide esculentin-1a(1−21)NH2 is beneficial for its multiple functions. Amino Acids 2015, 47, 2505−2519.

Braunstein, A.; Papo, N.; Shai, Y. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob. Agents Chemother. 2004, 48, 3127−3129.

Eisenberg, D.; Weiss, R. M.; Terwilliger, T. C. The helical hydrophobic moment: a measure of the amphiphility of a helix. Nature 1982, 299, 371−374.

Sriramulu, D. D.; Lunsdorf, H.; Lam, J. S.; Romling, U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 2005, 54, 667−676.

Maietta, G.; Grassi, L.; Esin, S.; Serra, I.; Scociapino, M. A.; Rinaldi, A. C.; Batoni, G. The semi-synthetic peptide Lin-SB056−21 in combination with EDTA exerts strong antimicrobial and antibiofilm activity against Pseudomonas aeruginosa in conditions mimicking Cystic fibrosis sputum. Int. J. Mol. Sci. 2017, 18, 1994.

Schneider-Futschik, E. K.; Paulin, O. K. A.; Hoyer, D.; Roberts, K. D.; Ziugas, J.; Baker, M. A.; Karas, J.; Li, J.; Velkov, T. Sputum active polymyxin lipopeptides: Activity against Cystic fibrosis Pseudomonas aeruginosa isolates and their interactions with sputum Biomolecules. ACS Infect Dis 2018, 4, 646−655.

Portel lineman, J.; Angeles-Boza, A. M. The antimicrobial peptide gad-1 clears Pseudomonas aeruginosa Biofilms under Cystic fibrosis conditions. Chembiochem 2021, 22, 1646−1655.

Bergsson, G.; Reeves, E. P.; McNally, P.; Chotirmall, S. H.; Greene, C. M.; Greally, P.; Murphy, P.; O’Neill, S. J.; McElvaney, N. G. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 2009, 183, 543−551.

Beaudoin, T.; Stone, T. A.; Glibowicka, M.; Adams, C.; Yau, Y.; Ahmadi, S.; Bear, C. E.; Grasemann, H.; Waters, V.; Deber, C. M. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Sci. Rep. 2018, 8, 14728.

Mattiazzo, M.; De Go bella, C.; Runti, G.; Mardrossian, M.; Bandiera, A.; Gennaro, R.; Scocchi, M. Peptidolytic activity of Escherichia coli oligopeptidase B against proline-rich antimicrobial peptides. J. Microbiol. Biotechnol. 2014, 24, 160−167.

Kai-Larsen, Y.; Luthje, P.; Chromek, M.; Peters, V.; Wang, X.; Holm, A.; Kadas, L.; Hedlund, K. O.; Johansson, J.; Chapman, M. R.; Jacobson, S. H.; Romling, U.; Agerberth, B.; Brauner, A. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog 2010, 6, e1001010.

Ridyard, K. E.; Overhage, J. The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics 2021, 10, 650.

Schito, A. M.; Piatti, G.; Caviglia, D.; Zaccari, G.; Zorzoli, A.; Marimpieri, D.; Alfieri, S. Bactericidal activity of non-cytotoxic cationic nanoparticles against clinically and environmentally relevant Pseudomonas sp. isolates. Pharmaceutics 2021, 13, 1411.

Goncalves, T.; Vasconcelos, U. Colour me blue: The history and the biotechnological potential of pyocyanin. Molecules 2021, 26, 927.

Thi, M. T. T.; Wibowo, D.; Rehm, B. H. A. Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci. 2020, 21, 8671.

Andrault, P. M.; Samsonov, S. A.; Weber, G.; Coquet, L.; Nazmi, K.; Bolscher, J. G.; Lalmanach, A. C.; Jouenne, T.; Bromme, D.; Pisabarro, M. T.; Lalmanach, G.; Lecaille, F. Antimicrobial peptide LL-37 is both a substrate of cathepsins S and K and a selective inhibitor of cathepsin L. Biochemistry 2015, 54, 2785−2798.